We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

AbCellera Biologics Inc (ABCL) NPV

Sell:$7.81 Buy:$7.83 Change: $0.56 (6.69%)
Market closed |  Prices as at close on 26 January 2022 | Switch to live prices |
Change: $0.56 (6.69%)
Market closed |  Prices as at close on 26 January 2022 | Switch to live prices |
Change: $0.56 (6.69%)
Market closed |  Prices as at close on 26 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

AbCellera Biologics Inc. (AbCellera) is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.

Contact details

2215 Yukon Street
V5Y 0A1
+1 (604) 5599005

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.36 billion
Shares in issue:
281.58 million
Life Sciences Tools & Services
US dollar
NASDAQ Comb. Composite

Key personnel

  • Carl L. Hansen
    Chief Executive Officer, Co-Founder, Director
  • Veronique Lecault
    Co-Founder, Chief Operating Officer, Director
  • Kevin Heyries
    Co-Founder, Head of Business Development
  • Andrew Booth
    Chief Financial Officer
  • Ester Falconer
    Chief Technology Officer
  • Tryn Stimart
    Chief Compliance Officer, Company Secretary, Chief Legal Officer
  • Neil Aubuchon
    Chief Commercial Officer
  • Neil Berkley
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.